Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

S Mudaliar, RR Henry, AJ Sanyal, L Morrow… - Gastroenterology, 2013 - Elsevier
Background & Aims Obeticholic acid (OCA; INT-747, 6α-ethyl-chenodeoxycholic acid) is a
semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, the natural …
被引用次数：1055 相关文章
[PDF] academia.edu

[PDF][PDF] CLINICAL—LIVER

S MUDALIAR, RR HENRY, AJ SANYAL… - …, 2013 - academia.edu
BACKGROUND & AIMS: Obeticholic acid (OCA; INT-747, 6a-ethyl-chenodeoxycholic acid)
is a semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, the …

[引用][C] Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

S Mudaliar, RR Henry, AJ Sanyal, L Morrow… - Gastroenterology, 2013 - cir.nii.ac.jp
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With
Type 2 Diabetes and Nonalcoholic Fatty Liver Disease | CiNii Research CiNii 国立情報学 …

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

S Mudaliar, RR Henry, AJ Sanyal, L Morrow… - …, 2013 - europepmc.org
Methods We performed a double-blind, placebo-controlled, proof-of-concept study to
evaluate the effects of OCA on insulin sensitivity in patients with nonalcoholic fatty liver …

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

S Mudaliar, RR Henry, AJ Sanyal, L Morrow… - 2013 - pubmed.ncbi.nlm.nih.gov
Background & aims Obeticholic acid (OCA; INT-747, 6α-ethyl-chenodeoxycholic acid) is a
semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, the natural …

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

S Mudaliar, RR Henry, AJ Sanyal, L Morrow… - …, 2013 - gastrojournal.org
Background & Aims Obeticholic acid (OCA; INT-747, 6α-ethyl-chenodeoxycholic acid) is a
semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, the natural …

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

S Mudaliar, RR Henry, AJ Sanyal, L Morrow… - Gastroenterology, 2013 - infona.pl
Obeticholic acid (OCA; INT-747, 6α-ethyl-chenodeoxycholic acid) is a semisynthetic
derivative of the primary human bile acid chenodeoxycholic acid, the natural agonist of the …

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

S Mudaliar, RR Henry, AJ Sanyal, L Morrow… - …, 2013 - hero.epa.gov
Background & Aims Obeticholic acid (OCA; INT-747, 6α-ethyl-chenodeoxycholic acid) is a
semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, the natural …

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

S Mudaliar, RR Henry, AJ Sanyal, L Morrow… - Gastroenterology, 2013 - infona.pl
Obeticholic acid (OCA; INT-747, 6α-ethyl-chenodeoxycholic acid) is a semisynthetic
derivative of the primary human bile acid chenodeoxycholic acid, the natural agonist of the …
[PDF] academia.edu

[PDF][PDF] CLINICAL—LIVER

S MUDALIAR, RR HENRY, AJ SANYAL… - …, 2013 - academia.edu
BACKGROUND & AIMS: Obeticholic acid (OCA; INT-747, 6a-ethyl-chenodeoxycholic acid)
is a semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, the …